The trial obtained equally its primary endpoints, with semaglutide two.4 mg demonstrating statistically important and exceptional improvements in liver fibrosis without any worsening of steatohepatitis, and also resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH in comparison to placebo.oneThey also can advise you